Kintor shares plunge after hair-loss drug flops in clinical trials
The company’s drug has failed to show a significant hair-boosting effect in Phase III trials, dashing investors’ hopes for a ground-breaking treatment for baldness Key Takeaways: The disappointing test results…
Recent Articles
RELATED ARTICLES
-
Plenty of room for growth in China’s hair transplant market
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- PegBio aims to bulk up its finances to deliver weight-loss drugs
- Innogen Pharma jostles for a slice of the weight-loss market
